Click image to enlarge
The
V-PLEX platform offers analytically validated singleplex and multiplex assay kits. Developed under rigorous design control, V-PLEX kits provide accurate and reproducible results with consistency from lot to lot. The V-PLEX Plus Human PlGF Kit enables the measurement of PlGF in a single-analyte format. For information on multiplexing PlGF with other analytes, please see
V-PLEX Plus Angiogenesis Panel 1 Human Kit.V-PLEX Plus kits include controls, wash buffer, and plate seals.
Related Key Terms:
Placenta growth factor, PGF, PGFL, PLGF, angiogenesis, vasculogenesis, endothelial cell growth, VEGFR-1/flt-1 receptor, melanoma
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Cardiovascular
|
|
|
Analyte(s)
|
|
PlGF
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
SECTOR Imager 6000
,
MESO SECTOR S 600MM
,
MESO QuickPlex SQ 120
|
|
|
Plate Type
|
|
96-well
|
|
|
Capture Antibody
|
|
Mouse Monoclonal
|
|
|
Detection Antibody
|
|
Goat Polyclonal
|
|
|
LLOD (Sensitivity)
|
|
0.21 pg/mL
|
|
|
Dynamic Range
|
|
0.21 - 800 pg/mL
|
|
|
Sample Type
|
|
Serum, EDTA Plasma, Urine, Cell Culture Supernatant, Cell Lysate
|
|
|
Recombinant standards
|
|
Expressed in E. coli
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Gene ID(s)
|
|
5228
|
|
|
UniProt ID(s)
|
|
P49763
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Angiogenesis Control 1
|
≤-70 °C
|
1 vial
(1 vial)
|
|
|
|
Angiogenesis Control 2
|
≤-70 °C
|
1 vial
(1 vial)
|
|
|
|
Angiogenesis Control 3
|
≤-70 °C
|
1 vial
(1 vial)
|
|
|
|
|
≤-70 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
Angiogenesis Panel 1 (human) Plate
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Diluent Assembly 11 (includes Diluent 7 – 50 mL, Diluent 11 – 5 mL)
|
≤-10 °C
|
1 each
|
|
|
|
|
RT
|
1 bottle
(100 mL)
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
MSD Blocker A
|
RT
|
1 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
1 bottle
(50 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Angiogenesis Control 1
|
≤-70 °C
|
5 vial
(1 vial)
|
|
|
|
Angiogenesis Control 2
|
≤-70 °C
|
5 vial
(1 vial)
|
|
|
|
Angiogenesis Control 3
|
≤-70 °C
|
5 vial
(1 vial)
|
|
|
|
|
≤-70 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
Angiogenesis Panel 1 (human) Plate
|
2-8 °C
|
5 each
(1 each)
|
|
|
|
Diluent Assembly 12 (includes Diluent 7 – 50 mL, Diluent 11 – 50 mL)
|
≤-10 °C
|
1 each
|
|
|
|
|
RT
|
1 bottle
(100 mL)
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
MSD Blocker A
|
RT
|
1 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
1 bottle
(50 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Angiogenesis Control 1
|
≤-70 °C
|
25 vial
(1 vial)
|
|
|
|
Angiogenesis Control 2
|
≤-70 °C
|
25 vial
(1 vial)
|
|
|
|
Angiogenesis Control 3
|
≤-70 °C
|
25 vial
(1 vial)
|
|
|
|
|
≤-70 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
Angiogenesis Panel 1 (human) Plate
|
2-8 °C
|
25 each
(1 each)
|
|
|
|
Diluent Assembly 12 (includes Diluent 7 – 50 mL, Diluent 11 – 50 mL)
|
≤-10 °C
|
5 each
|
|
|
|
|
RT
|
5 bottle
(100 mL)
|
|
|
|
|
RT
|
5 bottle
(50 mL)
|
|
|
|
MSD Blocker A
|
RT
|
5 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
5 bottle
(50 mL)
|
|
|
|
Product Inserts
|
|
|
|
Certificate of analysis
|
|
View More
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2 in patients with advanced hepatocellular cancer.
|
|
|
|
Phase I study of Dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
|
|
|
|
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948).
|
|
|
|
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two phase I trials in patients with advanced solid tumors.
|
|
|
|
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Meso Scale Japan 株式会社